BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017 /PRNewswire/ — Biosimilar Trastuzumab, co-developed by Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL), has been approved by ANVISA, the Brazilian regulatory agency, thro…